Study: NCT01852604

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samatasvir
Description: Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samatasvir
Description: Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samatasvir
Description: Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samatasvir
Description: Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samatasvir
Description: Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samatasvir
Description: Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samatasvir
Description: Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Samatasvir
Description: Samatasvir (IDX719) will be supplied as 25 mg and 50 mg oral tablets.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir will be supplied as 75 and 150 mg oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir will be supplied as 75 and 150 mg oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir will be supplied as 75 and 150 mg oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir will be supplied as 75 and 150 mg oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir will be supplied as 75 and 150 mg oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir will be supplied as 75 and 150 mg oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir will be supplied as 75 and 150 mg oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Simeprevir
Description: Simeprevir will be supplied as 75 and 150 mg oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: Ribavirin will be supplied as 200 mg oral tablets. Participants in the RBV-free arms experiencing non-response or virologic breakthrough during the treatment period will be offered RBV dosed according to the product label as an add-on to the participant's randomized treatment assignment.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: TMC647055 will be supplied as 150 mg oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC647055
Description: TMC647055 will be supplied as 150 mg oral capsules.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Description: Ritonavir will be supplied as 80 mg/mL oral solution.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir (RTV)
Description: Ritonavir will be supplied as 80 mg/mL oral solution.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg-IFN)
Description: Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg-IFN)
Description: Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg-IFN)
Description: Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg-IFN)
Description: Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg-IFN)
Description: Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg-IFN)
Description: Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg-IFN)
Description: Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pegylated interferon (Peg-IFN)
Description: Participants experiencing non-response or virologic breakthrough during the treatment period will be offered Peg-IFN (subcutaneous injection) dosed according to the product label as an add-on to the participant's randomized treatment assignment.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Samatasvir matching placebo
Description: Samatasvir matching placebo will be supplied for the 50 mg tablets used in Part A.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Samatasvir matching placebo
Description: Samatasvir matching placebo will be supplied for the 50 mg tablets used in Part A.